Leap Therapeutics Highlights Upcoming J.P. Morgan Conference Event
Leap Therapeutics Prepares for the J.P. Morgan Healthcare Conference
Leap Therapeutics, Inc. (Nasdaq: LPTX), a pioneering biotechnology firm dedicated to transforming oncology treatment, has announced an important presentation slated for a prestigious healthcare event. The company is focused on introducing innovative targeted and immuno-oncology therapeutics, marking significant strides toward advancing cancer care.
Key Presentation Details
Douglas E. Onsi, President and Chief Executive Officer of Leap Therapeutics, is set to deliver a corporate overview during the renowned J.P. Morgan Healthcare Conference. This high-profile event attracts leaders and innovators in the biotechnology landscape, offering a platform to discuss breakthrough developments and collaborative opportunities.
Event Schedule
Attendees can tune in to Leap's presentation scheduled for January 15, 2025, at 2:15 p.m. Pacific Time. This comprehensive overview will highlight the company's strategy, pipeline, and future prospects in oncology.
About Leap Therapeutics
Leap Therapeutics specializes in creating targeted therapies for cancer treatment, harnessing the power of the immune system to fight malignancies. Their lead candidate, DKN-01, is a humanized monoclonal antibody created to attack the Dickkopf-1 (DKK1) protein. This innovative therapy aims to treat various cancers, including esophagogastric, colorectal, and gynecological types.
Pipeline Development
In addition to DKN-01, Leap is advancing FL-501, another humanized monoclonal antibody that specifically targets the growth differentiation factor 15 (GDF-15) protein. This candidate is currently in preclinical stages and has the potential to broaden Leap's impact in the oncology field.
Live Webcast Accessibility
For those interested in learning more about Leap Therapeutics and its developments, a live broadcast of the presentation will be accessible on the Investors section of the company’s website. A replay of this pivotal event will also be available for a limited timeframe, ensuring that stakeholders can stay informed about Leap's progress.
Contact Information
For additional inquiries, Douglas E. Onsi is available at Leap Therapeutics. Potential investors and interested parties can also reach out to Matthew DeYoung for investor relations through their provided contact lines.
Frequently Asked Questions
What is Leap Therapeutics known for?
Leap Therapeutics focuses on developing targeted and immuno-oncology therapies to treat various types of cancer.
When will Leap's presentation at the J.P. Morgan Conference occur?
The presentation is scheduled for January 15, 2025, at 2:15 p.m. Pacific Time.
How can I access Leap Therapeutics' presentation?
A live webcast of the presentation will be available on Leap's Investor page, along with a replay for a limited time.
What are the key therapies developed by Leap?
Leap's leading therapies include DKN-01 and FL-501, targeting the DKK1 and GDF-15 proteins, respectively.
Who can I contact for more information?
Contact Douglas E. Onsi or Matthew DeYoung for further inquiries regarding Leap Therapeutics. Their contact information is available in the announcement.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.